Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Reports Positive Results For ReceptoPharm's RPI-78M in Multiple Sclerosis Animal Model
October 04, 2004

Nutra Pharma Corp., a biotechnology holding company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis has announced that its minority holding, ReceptoPharm, Inc. has reported the successful completion of studies in an animal model of Multiple Sclerosis (MS).

EAE (experimental allergic encephalomyelitis) is the standard benchmark animal methodology for the study of MS. ReceptoPharm's drug, RPI-78M, proved to be very effective in preventing the onset of disability in acute and chronic models of the disease. The drug was also very effective in preventing the infiltration of immune cells into the central nervous system. This research was conducted to confirm the reported benefits of similar products in immune mediated diseases such as Multiple Sclerosis and Rheumatoid Arthritis.

"The EAE study yielded the results we expected though we were pleasantly surprised at the reduced CNS infiltration by lymphocytes," commented Paul Reid, PhD, CEO of ReceptoPharm. "The results of this study complete the rationale for entering into clinical trials for the MS indication. We are actively working on one IND for the Phase II/III AMN (Adrenomyeloneuropathy) indication and when that is completed we will be in a good position to enter into MS trials," he added.

"These remarkable results provide supporting rationale for our microarray work with RPI-78M," commented James Flowers, President and Chief Scientific Officer of Eno Research and Development, Inc. (ERDI). "After reviewing this study, we expanded our efforts to include analysis of the interactions between the different cell types of the MS lesion," he continued. "Understanding how this compound affects the MS lesion and which genes it modulates, may help us understand the mechanism of action for RPI-78M." Nutra Pharma has engaged ERDI to study RPI-78M and its effects on gene expression using cDNA microarray technology. Their research aims to identify any potentially unique changes in gene expression that may be caused by the therapy.

"RPI-78M reduced the clinical symptoms by more than 80 percent," remarked neurologist Mitchell S. Felder, M.D. "There was also more than an 87 percent reduction in the number of EAE histopathologic lesions. If these results are duplicated in the human trials it could possibly revolutionize the treatment of MS. The results from an EAE model indicate that this drug may also have therapeutic potential for a great number of other neurologic conditions such as Acute Disseminated Encephalomyelitis, Transverse Myelitis, Krabbe's Leukodystrophy, Alexander's Disease, Canavan's Disease and Adrenoleukodystrophy," he concluded.

"These results are very encouraging," commented Rik Deitsch, CEO of Nutra Pharma. "The positive results of the animal model support our move into Phase II human clinical trials," he added.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The positive results from ReceptoPharm's animal model using RPI-78M should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: